Premium
Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival
Author(s) -
Liao WenTing,
Wang Xi,
Xu LiHua,
Kong QingLi,
Yu ChunPing,
Li ManZhi,
Shi Ling,
Zeng MuSheng,
Song LiBing
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24128
Subject(s) - lung cancer , immunohistochemistry , medicine , stage (stratigraphy) , western blot , pathology , cancer , oncology , survival analysis , clinical significance , reverse transcription polymerase chain reaction , carcinoma , cancer research , biology , gene expression , gene , paleontology , biochemistry
Abstract BACKGROUND: Lung cancer is 1 of the leading causes of cancer death worldwide, and the high mortality from this disease is caused mainly by the lack of efficient diagnostic strategies for early‐stage lung cancer. The objective of the current study was to investigate the expression pattern and clinicopathologic significance of centromere protein H (CENP‐H) in patients with nonsmall cell lung cancer (NSCLC). METHODS: The expression profile of CENP‐H in normal lung epithelial cells, NSCLC cell lines, NSCLC tissues, and adjacent noncancerous lung tissues were detected by reverse transcription‐polymerase chain reaction (RT‐PCR), real‐time RT‐PCR, and Western blot analysis. The expression level of CENP‐H in 223 NSCLC tissues was measured by immunohistochemistry staining. Statistical analysis was performed to evaluate the clinicopathologic significance of CENP‐H. RESULTS: The expression level of CENP‐H was much higher in cancer cell lines and lung cancer tissues than that in normal cells and adjacent noncancerous lung tissues, respectively. Immunohistochemical analysis revealed positive CENP‐H expression in 118 of 223 NSCLC tissues (52.9%). Statistical analysis revealed that CENP‐H expression was correlated strongly with clinical stage ( P =.018), tumor classification ( P =.03), and Ki‐67 expression ( P < .001). Patients with lower CENP‐H expression had better overall survival than patients with higher CENP‐H expression. Further analysis suggested that CENP‐H could predict prognosis only in patients with early‐stage disease. Multivariate analysis suggested that CENP‐H expression was an independent prognostic marker for survival in patients with NSCLC. CONCLUSIONS: The current results demonstrated that high CENP‐H protein expression was related to poor outcome in patients with NSCLC. CENP‐H may be used as a prognostic biomarker for patients lung patients, especially those with early‐stage NSCLC. Cancer 2009. © 2009 American Cancer Society.